Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Tuesday 12 March, 2019

AstraZeneca PLC

Director/PDMR Shareholding

RNS Number : 5981S
AstraZeneca PLC
12 March 2019
 

12 March 2019 12:00 GMT

 

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

 

AstraZeneca PLC (the Company) announces that, on 8 March 2019, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.

 

PDMR

Ordinary Shares granted under the AZDBP

Ordinary Shares granted under the AZPSP

Award price per Ordinary Share

Pascal Soriot

9,849

102,475

£62.87

Marc Dunoyer

4,874

48,690

£62.87

 

The AZDBP award represents the portion of each PDMR's annual bonus for 2018 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.

 

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2019 to 31 December 2021). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.

 

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2018, which is available on the Company's website at www.astrazeneca.com/annualreport2018.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Pascal Soriot

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£62.87

112,324

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

 

 

e)

 

Date of the transaction

 

 

8 March 2019

f)

 

Place of the transaction

 

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Marc Dunoyer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£62.87

53,564

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

 

 

e)

 

Date of the transaction

 

 

8 March 2019

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Gonzalo Viña

UK/Global

+44 203 749 5916

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jennifer Hursit

UK/Global

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma - Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

BioPharma - Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors; Corporate Access

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUUARRKNAOAAR

a d v e r t i s e m e n t